Analysts turned bullish on Eli Lilly (LLY) on Friday, betting on its obesity-drug leadership and expanding pipeline. Scotiabank raised its target to $1,605 from $1,300 and held an ‘Outperform’ rating, …
LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today
view original post